Skip to content

Two Intravenous Doses of Ketamine in Reducing the Oculocardiac Reflex in Adult Patients Undergoing Ophthalmic Surgery

Evaluation of Two Intravenous Doses of Ketamine in Reducing the Oculocardiac Reflex in Adult Patients Undergoing Ophthalmic Surgery: A Randomized Controlled Double-Blinded Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07708740
Enrollment
40
Registered
2026-07-16
Start date
2026-07-01
Completion date
2027-12-30
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ketamine, Oculocardiac Reflex, Ophthalmic Surgery

Brief summary

This study aims to evaluate whether a lower dose of ketamine (0.5 mg/kg IV) may be as effective as a higher dose (0.75 mg/kg IV) in reducing oculocardiac reflex (OCR) incidence in adult patients undergoing ophthalmic surgery.

Detailed description

The oculocardiac reflex (OCR) is a trigeminovagal reflex that can occur intraoperatively due to traction on extraocular muscles or pressure on the globe, resulting in bradycardia, arrhythmias, or asystole. Defined as a heart rate drop exceeding 20% from baseline, OCR is most frequently described in pediatric strabismus surgery, though its relevance persists in adult ophthalmic interventions involving similar stimuli. Optimal ketamine dosing in adults remains underexplored. Higher doses may enhance OCR protection but could also prolong emergence or increase psychomimetic effects.

Interventions

DRUG0.5 mg/kg intravenous ketamine

Patients will receive 0.5 mg/kg intravenous ketamine hydrochloride.

DRUG0.75 mg/kg intravenous ketamine

Patients will receive 0.75 mg/kg intravenous ketamine hydrochloride.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 65 years old. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I, II. * Scheduled for elective ophthalmic surgery involving extraocular muscle traction under general anesthesia.

Exclusion criteria

* Ketamine contraindications (e.g., hypersensitivity, uncontrolled hypertension) * History of cardiac arrhythmia or conduction disorder * Glaucoma or raised intraocular pressure * ASA status greater than II * Patient refusal.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of oculocardiac reflexDuring extraocular muscle traction (intraoperative)Incidence of oculocardiac reflex (OCR) in each group \[defined as ≥20% heart rate decrease from baseline or absolute bradycardia (HR\<50 bpm)\] sustained during extraocular muscles (EOMs) traction.

Secondary

MeasureTime frameDescription
Lowest recorded intraoperative heart rateIntraoperativelyThe lowest recorded intraoperative heart rate will be recorded.
Incidence of use of atropineIntraoperativelyIf oculocardiac reflex (OCR) (defined as \>20% drop in heart rate from the baseline or absolute bradycardia \<50 bpm) occurs, the surgeon will be ordered to stop extraocular muscle traction, and atropine increments (0.3 mg IV) will be administered.
Mean arterial pressureEvery 15 minutes till the end of surgery (Up to two hours)Mean arterial pressure (MAP) will be recorded throughout surgery, measured every 15 minutes.
Heart rateEvery 15 minutes till the end of surgery (Up to two hours)Heart rate (HR) will be recorded throughout surgery, measured every 15 minutes.
Time to emergenceTo eye opening (Up to one hour)Time to emergence from anesthesia will be recorded from the conclusion of anesthesia to eye opening.
Incidence of postoperative complications24 hours postoperativelyIncidence of postoperative complications such as nausea, vomiting, or hallucinations will be recorded.

Countries

Egypt

Contacts

CONTACTHebatullah S Abdelhamid, MD
drhebasalah593@gmail.com00201044512277

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026